MyoKardia Inc

MyoKardia — Investor Presentation (March 2017)

39 slides from MyoKardia's investor presentation, Mar 6, 2017

  1. Slide 1: Management Presentation March 2017: Pioneering Precision Cardiovascular Medicine

    (NASDAQ: MYOK) Management Presentation March 2017 Pioneering Precision Cardiovascular Medicine Q3 VERSION Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identi

  3. Slide 3: Rethinking Cardiovascular Disease

    Rethinking Cardiovascular Disease Our Mission: to change the world for patients with serious cardiovascular disease through bold and innovative science

  4. Slide 4: Investment Highlights

    Investment Highlights Lead product candidate MYK-461 for symptomatic obstructive HCM (oHCM) enrolling Phase 2 PIONEER-HCM study; topline results expected Q3 2017 Efficient pathway to registration based on functional improvement and clinical symptoms; no mortality-based endpoints Phase 1 underway for

  5. Slide 5: Cardiomyopathies Result from Three Distinct Types of Cardiac Muscle Disruptions

    Impaired relaxation Excessive contraction Inadequate contraction Normal contraction Dilated Cardiomyopathy (DCM) Hypertrophic Cardiomyopathy (HCM) Normal Heart Cardiomyopathies Result from Three Distinct Types of Cardiac Muscle Disruptions

  6. Slide 6: Addressing Large Patient Populations Segmented into Smaller, Well-Defined Subgroups

    MyoKardia Addressing Large Patient Populations Segmented into Smaller, Well-Defined Subgroups Hypertrophic Cardiomyopathy (630,000) Idiopathic Dilated Cardiomyopathy (900,000) Obstructive HCM (410,000) Non-obstructive HCM (220,000) Idiopathic DCM with unknown genetic cause(1) Genetic DCM (gDCM) (360

  7. Slide 7: Pipeline of First-in-Class Targeted Therapies

    Pipeline of First-in-Class Targeted Therapies Research Discovery Phase 1 Phase 2 Upcoming Milestone(s) MYK-461 Phase 2 PIONEER-HCM topline data Q3 2017 Initiate Phase 2 EXPLORER-HCM trial H2 2017 Initiate Phase 2 trial in nHCM patients H2 2017 MYK-491 Phase 1 SAD topline data Q3 2017 Initiate Phase

  8. Slide 8: Symptomatic Obstructive HCM: Our PIONEER-HCM Study Population

    Symptomatic Obstructive HCM: Our PIONEER-HCM Study Population Physiological complication of HCM; thickened muscle obstructs left ventricular outflow tract (LVOT) Earlier onset of severe symptoms of HF and/or death vs. non-obstructive HCM(1)(2) Surgical relief of obstruction improves symptoms and fun

  9. Slide 9: Registration Program Plan Enables Efficient Execution of Pivotal Trial

    Registration Program Plan Enables Optimal Design and Efficient Execution of Pivotal Trial Reduce cardiac muscle contractility Alleviate LVOT pressure gradient Improved clinical benefit MYK-461 demonstrates proof of mechanism in HV and HCM patients ü Data showing reduction of gradient in two patients

  10. Slide 10: PIONEER-HCM: A Phase 2 Study in Symptomatic oHCM

    PIONEER-HCM: A Phase 2 Study in Symptomatic oHCM Study Goals Evaluate safety and tolerability of repeated doses of MYK-461 in patients with symptomatic obstructive HCM Gain experience with MYK-461 in an outpatient setting Assess level of reduction in LVOT gradient; confirm prior conclusions that gra

  11. Slide 11: PIONEER-HCM Study Details

    At the end of week 4, pre-specified criteria allow for an increase (either 5 or 10mg QD), decrease (5mg QD) or no change in dose based on % decrease from baseline in LVEF PIONEER-HCM Study Details Starting Dose Adjusted Dose Week 4: Dose Adjustment(1) Screening Week 12: Primary Endpoint Washout MYK-

  12. Slide 12: Beyond PIONEER-HCM: Clinical Development Plan to Support Registration in oHCM

    Beyond PIONEER-HCM: Efficient Clinical Development Plan to Support Registration for MYK-461 in oHCM Ph1 SAD trial – HV Study Description Primary EP Trial Size Treatment Duration Potential Data Catalyst(s) Phase 2 (PIONEER-HCM) Effect of MYK-461 on LVOT gradient LVOT gradient 10 12 weeks Topline data

  13. Slide 13: Dilated Cardiomyopathy: Devastating Disease with No Approved Therapies

    DCM Heart Dilated Cardiomyopathy (DCM): Devastating Disease with No Approved Therapies Burden of Disease Standard of Care Chronic, progressive, debilitating heart failure that can shorten life Shortness of breath, chest pain, fatigue; interfere with activity of daily life Increased risk of sudden ca

  14. Slide 14: Therapeutic Hypothesis for MYK-491: a Novel Cardiac Myosin Activator

    Therapeutic Hypothesis for MYK-491: a Novel Cardiac Myosin Activator Targeting the Underlying Cause of DCM Inadequate engaged cross-bridges MYK-491 Increase extent of contraction Restores cardiac output in dilated heart Potential for beneficial remodeling Goal: improve symptoms of HF in patients wit

  15. Slide 15: MYK-491 in a Paced HF Dog Model

    MYK-491 in a Paced HF Dog Model: Restores Heart Function (Systole) without Impairing Relaxation Dose dependent increase in contractility No significant impact on diastolic relaxation * p < 0.05 * * * * * * Consistent results observed across multiple pre-clinical model systems

  16. Slide 16: MYK-491 Clinical Development Pathway

    Today MYK-491 Clinical Development Pathway Grounded in Principles of MyoKardia Precision Medicine Trial # Description Trial Objective(s) Trial Initiation Topline Results 001 Ph1 Single ascending dose (SAD) Safety, tolerability, Proof of Mechanism (POM) January 2017 Q3 2017 002 Ph1 Multiple ascending

  17. Slide 17: Beyond Our Two Clinical Programs: Significant Opportunity Remains

    Myosin light chain β Myosin heavy chain Troponin T α Tropomyosin Troponin I Actin Myosin binding protein C Current clinical-stage programs: Formation of myosin-actin crossbridge MyoKardia pipeline programs based on validated genetic targets Plus: additional validated targets Beyond Our Two Clinical

  18. Slide 18: Value Inflection Catalysts From Multiple Programs

    Value Inflection Catalysts From Multiple Programs: Strong Momentum and Execution from 2016 Expected to Continue in 2017 2016 2017 HCM / MYK-461 Milestone DCM / MYK-491 Milestone Corporate Milestone Q3 2017: Topline data from Phase 1 SAD trial of MYK-491 Q3 2017: Topline data from PIONEER-HCM H2 2017

  19. Slide 19: Thank you!

    Thank you! g MyoKardia

  20. Slide 20: Appendices

    Appendices SS] MyoKardia

  21. Slide 21: Cardiac Muscle Disruptions Caused by Defective Contractile Proteins

    Heart Muscle Fibers Myofibril Normal Sarcomere Actin thin filament Myosin thick filament Actin-myosin cross-bridge Force-producing myosin head Cardiac Muscle Disruptions Caused by Defective Contractile Proteins

  22. Slide 22: Product Candidates Designed to Correct the Underlying Causal Defects

    DCM Sarcomere Inadequate engaged cross-bridges HCM Sarcomere Too many engaged cross-bridges MYK-461 MYK-491 Normal Sarcomere MyoKardia’s Product Candidates are Designed to Correct the Underlying Causal Defects

  23. Slide 23: MyoKardia Has Created the World's Leading Cardiomyopathy Registry (SHaRe)

    MyoKardia Has Created the World’s Leading Cardiomyopathy Registry The Sarcomeric Human Cardiomyopathy Registry (SHaRe) supports: Research (target discovery, etc.) Clinical development and registration Patient-caregiver community connectivity 11 centers, 10,000+ patients …and growing World-class acad

  24. Slide 24: How We Intend to Leverage SHaRe to Augment Corporate Capabilities

    Initial Examples of How We Intend to Leverage SHaRe to Augment Corporate Capabilities Natural History of Disease Role of Mutations Mechanistic Hypotheses Comprehensive picture of disease natural history Define unmet needs Identify subpopulations to study Understand the role of genetic mutations in t

  25. Slide 25: Current Standard of Care in oHCM

    Inadequate Therapeutic Options Current options used off-label: beta blockers, non-dihydropyridine calcium channel blockers, disopyramide Address symptoms only (vs. underlying cause of HCM) and do not appear to affect disease progression Tolerability limited by side effects High rate of non-responder

  26. Slide 26: MYK-461 Registration Program in oHCM Supported by FDA Interactions

    MYK-461 Registration Program in oHCM Supported by FDA Interactions Phase 2 trials to explore all above measures, allowing for final determination of pivotal trial’s primary endpoint (function or symptoms) Formal Regulatory Feedback Type C meeting held in July 2016 Mortality-based efficacy endpoints

  27. Slide 27: Successful Phase 1 Program: MYK-461 Well-Tolerated and Modulates Causal Disease Pathway

    In addition to 22 healthy volunteers across Phase 1 SAD and MAD trials who received placebo. Summary Phase 1 Program 86 healthy volunteers (HV) and 15 HCM patients dosed with MYK-461 across three Phase 1 studies(1) Safety Favorable safety profile observed across a meaningful dose range (1-144mg sing

  28. Slide 28: Three Phase 1 Trials of MYK-461 in HCM Patients and Healthy Volunteers

    Three Phase 1 Trials of MYK-461 in HCM Patients and Healthy Volunteers MYK-461-001 MYK-461-002 MYK-461-003 Single Ascending Dose (SAD) Trial in HCM Patients SAD Trial in Healthy Volunteers Multiple Ascending Dose (MAD) Trial in Healthy Volunteers Trial Design Open-label, sequential-group, SAD study

  29. Slide 29: MYK-461-001: SAD Study in HCM Patients

    MYK-461-001: SAD Study in HCM Patients Age (mean ± SD) 41.3 ± 14.7 years Sex 7 male (47%), 8 female (53%) NYHA Class 13 class I (87%), 2 class II (13%) Background HCM Medication None: 3 (20%) Beta blockers: 10 (67%) Calcium channel blockers: 4 (27%) Disopyramide: 1 (13%) Left Ventricular Ejection Fr

  30. Slide 30: Clinical Proof of Mechanism: Dose-Dependent PD Response

    Clinical Proof of Mechanism: Dose-Dependent PD Response Measured by Independent Biomarkers of Contractility SAD Results: Response at 2 Hours NOTE: Data represent mean ± SEM. Healthy Volunteers HCM Patients

  31. Slide 31: MYK-461 Shows Dose-Dependent Effect Differentiated from Placebo

    MYK-461 Shows Dose-Dependent Effect Clearly Differentiated from Placebo; Confirms Cessation of Single Dose Drug Activity at 48+ Hours Healthy Volunteers HCM Patients NOTE: Data represent mean ± SEM.

  32. Slide 32: Two Patients with LVOT Obstruction Administered Single Doses of MYK-461

    Two subjects enrolled in 001 study had a history of obstruction, and displayed a provocable LVOT pressure gradient Each patient administered single 96 mg dose of MYK-461 Two Patients with LVOT Obstruction Administered Single Doses of MYK-461 Phase 1 (SAD Trial in HCM Patients) LVOT Obstruction in a

  33. Slide 33: Drug Exposure Associated with Reductions in Contractility and LVOT Gradient

    Drug Exposure (PK) Contractility LVOT Obstruction Drug Exposure Associated with Reductions in Contractility and LVOT Gradient in Both Patients Dosed in Phase 1 Trial [MYK-461] (μg/mL) LVEF (%) LVOT Gradient (mmHg) Conclusions Both patients’ gradients were reduced following single dose (96 mg) of MYK

  34. Slide 34: Repeated Daily Dosing Also Demonstrates Clinical Proof of Mechanism

    Repeated Daily Dosing Also Demonstrates Clinical Proof of Mechanism MAD Results in Healthy Volunteers: Response at Day 25 Further data on MAD results available in H1 2017 NOTE: Data represent mean ± SEM.

  35. Slide 35: Hypothesis-Based Dosing in PIONEER-HCM Allows for Streamlined Phase 2 Design

    Hypothesis-Based Dosing in PIONEER-HCM Allows for Streamlined Design and Execution of Phase 2 Trial Starting Dose Adjusted Dose Trial Design Implications Adjust starting dose to target ~15-20% relative reduction in LVEF Incorporate multiple dose data from oHCM patients into PK/PD model Further defin

  36. Slide 36: Summary Development Plan for Additional Indications for MYK-461

    Summary Development Plan for Additional Indications for MYK-461 Additional information on development plan to be shared in 2017 Non-obstructive HCM (nHCM) Pediatric HCM No medical or surgical therapies available other than transplant In total, ~220,000 patients in U.S. (~33% of HCM patients)(1) Dosi

  37. Slide 37: Robust Data Set Shows MYK-491 Improves Systolic Function without Diastolic Impairment

    Heart Failure Dog Robust Data Set Shows MYK-491 Can Improve Systolic Function without Diastolic Impairment Across Multiple Animal Model Systems Consistent results observed across multiple pre-clinical model systems Healthy Dog Pig Increase extent of contraction Minimal impact on diastole / relaxatio

  38. Slide 38: Healthy Dog: Increases Contractility without Diastolic Impact

    Healthy Dog: Increases Contractility without Diastolic Impact Dose dependent increase in stroke volume (SV) Dose dependent and reversible positive inotropy Contractility Parameters Diastolic / Relaxation Parameters In same experiments, no meaningful changes in diastolic relaxation, as measured by LV

  39. Slide 39: Pig Model: Increases Systolic Function without Impairment of Diastole

    Pig Model: Increases Systolic Function without Impairment of Diastole in a Second Large Mammal Model Dose dependent increase in contractility No significant impact on diastolic relaxation Contractility Parameter Diastolic / Relaxation Parameter * ** * p < 0.05 ** p < 0.01 **

MyoKardia — Investor Presentation (March 2017) on 6ix